Home → E-shop → Antiviral compounds → Maraviroc – CAS 376348-65-1

Maraviroc – CAS 376348-65-1

Maraviroc – CAS 376348-65-1 is provided by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

99 %

Package contents

Maraviroc

This compound is for research use only. We do not sell to patients.

Amount

100 mg	€ 500	Stock
1 g	€ 3500	Stock
Do you want custom amount?			Custom amount

Amount

100 mg

€ 500

Stock

1 g

€ 3500

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 376348-65-1

IUPAC name: 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide

Other names: Selzentry, UK 427857

Molecular weight: 513.67 g/mol

Molecular formula: C₂₉H₄₁F₂N₅O

InChI: InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1

Description

Maraviroc is an antagonist of the C-C motif chemokine receptor CCR5, which is involved in the cell penetration process by HIV. As a CCR5 receptor antagonist, Maraviroc has a therapeutic application as an antiviral drug for the treatment of HIV infection. Maraviroc is sold under the brand names of Celsentry (EU) or Selzentry (US).

Chemicals are distributed worldwide

Buy Maraviroc now, get your order in 48 hours.

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Woollard, S. M., & Kanmogne, G. D. (2015). Maraviroc: a review of its use in HIV infection and beyond. Drug design, development and therapy, 5447-5468.
MacArthur, R. D., & Novak, R. M. (2008). Maraviroc: the first of a new class of antiretroviral agents. Clinical Infectious Diseases, 47(2), 236-241.
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., … & Mayer, H. (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. New England Journal of Medicine, 359(14), 1429-1441.